| Assay ID | Title | Year | Journal | Article |
|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID417925 | Oral bioavailability in dog | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID414350 | Clearance in dog | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID414332 | Antagonist activity at rat P2X3 receptor expressed in CHO cells by FLIPR | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID414341 | Tmax in rat at 2 mg/kg, po administered as single dose | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID414345 | AUC in rat at 2 mg/kg, po administered as single dose | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID417923 | Inhibition of 5HT6 receptor | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID414333 | Antagonist activity at human P2X2/3 receptor expressed in 1321n1c cells by FLIPR | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID414349 | Oral bioavailability in rat at 2 mg/kg administered as single dose | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID417912 | Antagonist activity at rat recombinant P2X3 receptor expressed in CHO cells by FLIPR assay | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID414340 | Tmax in rat at 2 mg/kg, iv administered as single dose | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID417917 | Inhibition of P2X5 receptor | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID417926 | Half life in dog | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID417920 | Inhibition of histamine H2 receptor | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID414344 | AUC in rat at 2 mg/kg, iv administered as single dose | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID417921 | Inhibition of 5HT2A receptor | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID414348 | Clearance in rat at 2 mg/kg, iv administered as single dose | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID417911 | Oral bioavailability in dog | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID417919 | Inhibition of ML1 receptor | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID1627256 | Intrinsic clearance in human liver microsomes at 1 to 2.5 uM in presence of NADPH | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
| New P2X3 receptor antagonists. Part 1: Discovery and optimization of tricyclic compounds. |
| AID1627258 | Ratio of efflux to influx in human Caco2 cells | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
| New P2X3 receptor antagonists. Part 1: Discovery and optimization of tricyclic compounds. |
| AID417918 | Inhibition of P2X7 receptor | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID1627253 | Antagonist activity at human recombinant P2X3 receptor expressed in HEK293-Tet-on cells assessed as alpha,beta-methylene-ATP-stimulated Ca2+ influx by Fluo-4 assay | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
| New P2X3 receptor antagonists. Part 1: Discovery and optimization of tricyclic compounds. |
| AID417922 | Inhibition of 5HT3 receptor | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID1627257 | Permeability in vinblastine-treated human Caco2 cells | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
| New P2X3 receptor antagonists. Part 1: Discovery and optimization of tricyclic compounds. |
| AID414586 | Half life in dog | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID417914 | Inhibition of P2X1 receptor | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID417913 | Antagonist activity at human recombinant P2X2/3 receptor expressed in human 1321N1 cells by FLIPR assay | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID414347 | Half life in rat at 2 mg/kg, po administered as single dose | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID1627255 | Kinetic solubility of the compound in phosphate buffer at pH 7.4 by HPLC analysis | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
| New P2X3 receptor antagonists. Part 1: Discovery and optimization of tricyclic compounds. |
| AID417915 | Inhibition of P2X2 receptor | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID417916 | Inhibition of P2X4 receptor | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID417927 | Ratio of permeability from basolateral to apical side over apical to basolateral side in human Caco-2 cells | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID1627259 | Inhibition of human ERG relative to control | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
| New P2X3 receptor antagonists. Part 1: Discovery and optimization of tricyclic compounds. |
| AID414343 | Cmax in rat at 2 mg/kg, po administered as single dose | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID414342 | Cmax in rat at 2 mg/kg, iv administered as single dose | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID417924 | Clearance in dog | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID414346 | Half life in rat at 2 mg/kg, iv administered as single dose | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. |
| AID1346621 | Human P2X3 (P2X receptors) | 2010 | British journal of pharmacology, Jul, Volume: 160, Issue:6
| AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |